Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-104971
Filing Date
2025-08-07
Accepted
2025-08-07 16:03:13
Documents
72
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q aldx-20250630.htm   iXBRL 10-Q 2279270
2 EX-10.1 aldx-ex10_1.htm EX-10.1 27586
3 EX-31.1 aldx-ex31_1.htm EX-31.1 18003
4 EX-31.2 aldx-ex31_2.htm EX-31.2 18032
5 EX-32.1 aldx-ex32_1.htm EX-32.1 13930
6 GRAPHIC img131811186_0.jpg GRAPHIC 232740
  Complete submission text file 0000950170-25-104971.txt   8370043

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aldx-20250630.xsd EX-101.SCH 965158
75 EXTRACTED XBRL INSTANCE DOCUMENT aldx-20250630_htm.xml XML 1269632
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36332 | Film No.: 251193803
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)